Zhejiang Garden Biopharmaceutical (300401.SZ) signed a new drug R&D project cooperation agreement with the Guangzhou National Laboratory.

Zhejiang Garden Biopharmaceutical (300401.SZ) announced that it recently signed a "25-Hydroxycholesterol New Drug R&D Project Cooperation Agreement" with the Guangzhou National Laboratory. Both parties agreed to cooperate, through the establishment of a joint venture company, to advance the R&D, registration, production, and commercialization of 25-hydroxycholesterol and its prodrug broad-spectrum antiviral drugs. The candidate drug has significant market potential in the broad-spectrum antiviral field. The joint venture company will be led by the Company for subsequent operations, with the Company holding no less than 51% equity. The signing of this cooperation agreement marks the Company's formal entry into the field of innovative drug R&D. If subsequent new drug R&D and commercialization achieve substantive breakthroughs, it will create a new performance growth curve for the Company and further enhance its core competitiveness and industry influence. Currently, the project is still in the early stage of R&D, and both project progress and R&D results are subject to uncertainty.